Instructions for Broncho-munal capsules
English Product Name
Broncho-munal P
Release Form
Capsules
Description Broncho-munal
The capsules are solid gelatin, size No. 3, opaque, with a white body and a blue lid; the contents of the capsules are light beige powder.
1 caps.
standardized bacterial lysate lyophilisate (OM-85) 20 mg,
including lyophilized lysates of bacteria (Haemophilus influenzae, Streptococcus pneumoniae, Streptococcus viridans, Streptococcus pyogenes, Klebsiella pneumoniae, Klebsiella ozaenae, Staphylococcus aureus, Moraxella catarrhalis) 3.5 mg
Accessories: propyl gallate (anhydrous), sodium glutamate (anhydrous), magnesium stearate, pregelatinized starch, mannitol.
The composition of the capsule shell: indigotin (E132), titanium dioxide (E171), gelatin.
10 pcs - blisters (1) - cardboard packs.
10 pcs - blisters (3) - cardboard packs.
Storage conditions for the Broncho-Munal®
The drug should be stored in a place inaccessible to children at temperatures from fifteen° to twenty-five° C.
Expiration date of the drug Broncho-munal®
The shelf life is five years.
ATX codes
L03AX Other immunostimulators
Clinical and pharmacological groups / Group affiliation
Immunostimulating drug of bacterial origin
Active ingredient
lyophilized lysates of bacteria: Haemophilus influenzae, Streptococcus pneumoniae, Streptococcus viridans, Streptococcus pyogenes, Klebsiella pneumoniae, Klebsiella ozaenae, Staphylococcus aureus, Moraxella catarrhalis
Pharmacotherapeutic group Broncho-munal
IBP
Pharmacological effect Broncho-munal
A bacterial agent, an immunomodulator, increases immunity against respiratory tract infections.
After this agent is taken, the bacterial lysate accumulates in Peyer patches of the gastrointestinal mucosa, particularly those in the small intestine. Antigen-presenting cells in Peyer plaques are activated by the bacterial lysate and subsequently stimulate other cell types (B cells), which are responsible for specific immunity. The number of circulating B cells increases, leading to increased production of polyclonal antibodies, especially serum IgG and IgA, secreted by the respiratory tract mucosa and salivary glands.
It influences non-specific immunity by stimulating white blood cells, which is characterized by an increase in the number of myeloid and lymphoid cells, as well as selective increase in the expression of receptors on the surface.
Testimony Broncho-munal
Respiratory tract infections (as part of complex therapy as an immunomodulatory agent) in children aged 6 months or older and in adults (depending on the formulation used).
To prevent recurring infections in a person's airways and acute exacerbations of chronic bronchitis.
Method of use, course and dosage Broncho-munal
They are taken by mouth a single dose (depending on the person's age) once a day.
- Nosology Broncho-munal (ICD codes)
- J00
- Acute nasopharyngitis (runny nose)
- J02
- Acute pharyngitis
- J03
- Tonsillitis acute
- J04
- Acute laryngitis and tracheitis
- J06.9
- Acute upper respiratory infection, unspecified
- J10
- Influenza due to identified seasonal influenza virus
- J15
- Bacterial pneumonia, not elsewhere classified
- J20
- Acute bronchitis
- J31.0
- Chronic rhinitis
- J31.2
- Chronic pharyngitis
- J35.0
- Chronic tonsillitis
- J37
- Chronic laryngitis and laryngotracheitis
- J42
- Chronic bronchitis, unspecified